Investor AB
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Investor AB reported 12 stock positions worth $5.2 billion. Its top holding was Nasdaq (NDAQ) at 99.6% of the portfolio, followed by Mediwound (MDWD, 0.3%) and Microchip Technology (MCHP, 0.0%). Compared with Q2 2025, it opened 3 new positions, sold out of 4 and added to 2. The biggest buy was Teradyne (TER, shares +80%) and the biggest sale an exit from Millicom Intl Cellular (TIGO).
- Most Recent 13F
- Q2 2026
- Location
- STOCKHOLM, V7
- CIK
- 0000889232
- Portfolio Value
- $5.2B (Q3 2025)
- SEC Filing
- 0001493152-25-023420 ↗ filed Nov 14, 2025
Holdings Value
Holdings 12 stocks · $5.2B
| NDAQ Nasdaq Inc. | 99.56% | 58,182,426 | $5.1B | No change |
| MDWD Mediwound Ltd. | 0.30% | 872,093 | $15.7M | No change |
| MCHP Microchip Technology Inc. | 0.03% | 25,000 | $1.6M | No change |
| TER Teradyne Inc. | 0.02% | 9,000 | $1.2M | Add +80.0% |
| CHKP Check Point Software Tech | 0.02% | 5,000 | $1.0M | Add +66.7% |
| CLBT Cellebrite Di Ltd. | 0.01% | 40,000 | $741K | No change |
| CCL Carnival Corp. | 0.01% | 21,000 | $607K | No change |
| ORCL Oracle Corp. | 0.01% | 2,000 | $562K | New |
| KYIV Kyivstar Group Ltd. | 0.01% | 35,000 | $438K | New |
| WHR Whirlpool Corp. | 0.01% | 3,700 | $291K | No change |
| SSNC Ss&c Technologies Holdings | 0.00% | 2,500 | $222K | New |
| BMRN Biomarin Pharmaceutical Inc. | 0.00% | 3,700 | $200K | No change |
Portfolio Sells Q2 2025 → Q3 2025
Portfolio Buys Q2 2025 → Q3 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 7 | $14.4B | AZN, NDAQ, MDWD, CLBT, MU |
| Q1 2026 | 10 | $15.1B | AZN, NDAQ, MDWD, CLBT, COHR |
| Q4 2025 | 12 | $5.7B | NDAQ, MDWD, COF, COHR, CELLEBRITE DI LTD |
| Q3 2025 | 12 | $5.2B | NDAQ, MDWD, MCHP, TER, CHKP |
| Q2 2025 | 13 | $5.2B | NDAQ, MDWD, MCHP, TIGO, CDNS |
| Q1 2025 | 13 | $4.4B | NDAQ, MDWD, TIGO, CDNS, MCHP |
| Q4 2024 | 8 | $4.5B | NDAQ, MDWD, CHKP, CLBT, CCL |
| Q3 2024 | 7 | $4.3B | NDAQ, MDWD, CHKP, ONTO, COHR |
| Q2 2024 | 6 | $3.5B | NDAQ, ONTO, CHKP, CCL, COHR |
| Q1 2024 | 10 | $3.7B | NDAQ, MU, AMAT, ONTO, CHKP |